Non-opioid pain treatments

Source date: 2026-11-09. Recorded in this review: November 10, 2026.

Evidence: Sponsor-reported randomized Phase 2 topline.

Vaneltix/Hyloris’s November 9 release reports VNX001-111 (NCT05737121), a randomized, double-blind, four-arm Phase 2 trial in 153 adults with acute IC/bladder-pain-syndrome flares. A single intravesical instillation of alkalinized lidocaine plus heparin (Alenura) was compared with placebo, lidocaine alone and heparin alone.

The sponsor says the 12-hour summed pain-intensity-difference endpoint favored the combination versus all three comparators, with reported p-values <.01, and supportive 24-hour findings. No effect sizes, confidence intervals, exact arm denominators or comparative harms rates are supplied in the appraised release. Statistical significance alone does not establish the size or durability of relief.

This is acute flare treatment, not cure of chronic IC/BPS. The specific formulation remains investigational; use of its components does not establish its FDA approval. Preparations for a 505(b)(2) NDA are ongoing, with no verified filing or decision date. Full efficacy and safety tables are the next useful evidence.

Sources: vaneltix.com · source page; ClinicalTrials.gov · NCT05737121.

Source date: 2026-11-10. Recorded in this review: November 10, 2026.

Evidence: New randomized Phase 4 pilot protocol; no results.

First posted November 10, NCT07928011 plans 40 adults undergoing unilateral total-knee replacement. The open-label randomized pilot compares standard multimodal care with the same care plus suzetrigine: a 100-mg loading dose followed by 50 mg every 12 hours for 14 days. Both groups can receive breakthrough opioids; this is not an opioid-free pathway.

The registry’s primary endpoints are enrollment, adherence and completeness of data collection. Cumulative opioid use is secondary; pain, independent walking and function are separate outcomes. No efficacy or comparative harms are established. Suzetrigine’s existing adult acute-pain approval is not a new chronic-pain indication or proof of better arthroplasty recovery. Not yet recruiting: January 2027 start, March 2027 primary completion and April 2027 final completion are estimates, not promised results.

Next milestones: Suzetrigine TKA feasibility-pilot start: 2027-01 (Registry estimate; not yet recruiting); Suzetrigine TKA feasibility-pilot primary completion: 2027-03 (Registry estimate); Suzetrigine TKA feasibility-pilot final completion: 2027-04 (Registry estimate).

Sources: ClinicalTrials.gov · NCT07928011.

Source date: 2026-11-10. Recorded in this review: November 10, 2026.

Evidence: Administrative registry timing update; excluded from alerts.

The November 10 NCT07504601 record moves estimated start from November 11 to November 15, 2026. It remains not yet recruiting, without results or verified first dosing. Estimated primary completion December 31, 2030 and final completion December 31, 2031 are unchanged. This updates the calendar only; it supplies no patient analgesic benefit or new safety result.

Next milestones: HNK experimental-pain estimated start; supersedes November 11: 2026-11-15 (Registry estimate; not yet recruiting).

Sources: ClinicalTrials.gov · NCT07504601.

Related finding, recorded once: ACR retatrutide knee-pain abstracts; clinical symptom relief remains separate from structural repair.

Coverage and remaining gaps: Reviewed full saved topic corpus and current scope/state;1,422/1,422 broad ClinicalTrials.gov pain-query records across 15 pages for November 3–10 retrieved, plus saved named IDs within 76/76 combined records; incidental oncology/surgery matches excluded and retrieval not treated as full appraisal. Selected Alenura/suzetrigine/HNK sources appraised. Cebranopadol NDA excluded from this non-opioid topic because it activates mu-opioid receptors. focused_incomplete; complete worldwide papers/supplements, non-US registries, regulator-label/hold census, original conference recordings and long-form informal-source appraisal remain incomplete. Full-success timestamps and baseline flags must remain unchanged. Alenura effect sizes/CI/arm-level harms missing. Broad registry retrieval not exhaustive appraisal. Original full Xenon poster denominators and SUTKA protocol remain gaps; no fresh chronic-neuropathy efficacy established.

Informal-source coverage: Targeted Reddit/Journavx/podcast searches retrieved uncontrolled patient/clinician anecdotes with conflicting experiences, including Octoberdiscussion threads and November 4 comment. No general efficacy/approval inference. Original long-form recordings remain partial.

Full coverage record.

Source date: 2026-11-04. Recorded in this review: November 6, 2026.

Novo’s November 4 report confirms completion of the CagriSema Phase 2 study (NCT06797869) in type 2 diabetes with painful diabetic peripheral neuropathy, using weekly 2.4/2.4 mg versus placebo. This is not a new completion or first efficacy disclosure: the saved September 21 sponsor presentation already reported a 32-week pain-score signal (−2.4 versus −1.3 points; analysis n=141). The registry lists 142 actual participants; do not interchange those denominators.

The November update adds no new numerical efficacy or comparative harms. Its useful nuance is the proposed 2027 Phase 3 trial with a “novel asset,” which is not identified. Do not automatically call the future intervention CagriSema or equate the earlier pain-score signal with established nerve repair, function or long-term safety. The trial remains a sponsor initiation forecast, without a matched public protocol or actual first dose.

Earlier September 21 evidence and limitations remain separate; the new asset’s identity and full design need confirmation.

Sources: Primary source; ClinicalTrials.gov · NCT06797869; novonordisk.com · PDF document.

Source date: 2026-11-04. Recorded in this review: November 6, 2026.

NCT07915947 plans 28 healthy adults aged 18–55, comparing oral LTG-321 alone with LTG-321 plus itraconazole 200 mg, a strong CYP3A inhibitor. LTG-321 is a new small-molecule NaV1.8 inhibitor being developed for non-opioid analgesia. Primary endpoints measure drug/metabolite exposure, peak concentrations and half-life, not pain relief. Numerical LTG-321 dose is not disclosed in the appraised record.

Not yet recruiting: December 4 start and December 24, 2026 primary completion are estimates. No results, patient analgesic benefit, comparative safety or U.S. approval are established. Interaction testing can inform future dosing restrictions but is not a test of superior pain control.

Sources: ClinicalTrials.gov · NCT07915947.

Source date: 2026-11-06. Recorded in this review: November 6, 2026. Administrative update; excluded from alerts.

The NCT07504601 update moves estimated start from November 8 to November 11, 2026. Status remains not yet recruiting, with no posted results. Primary December 31, 2030 and final December 31, 2031 completion estimates are unchanged. This supersedes the prior estimate without demonstrating first dosing, efficacy or a safety finding.

Sources: ClinicalTrials.gov · NCT07504601.

Related findings, recorded once: ACR schedules detailed retatrutide knee-pain reports (Lilly · news release).

Coverage and remaining gaps: focused_incomplete; CagriSema neuropathy numerical efficacy/harms and identity of proposed Phase 3 novel asset remain undisclosed. New TIPS registry posting was checked against a March 2026 paper; not treated as a newly demonstrated November effect.; Complete worldwide clinical, safety and informal-source appraisal remains unfinished; preserve prior full-success timestamps and baseline flags.

Informal-source coverage: Targeted Journavx/pain/NaV1.8 discussions and management announcements reviewed. Patient anecdotes do not establish chronic-pain efficacy or label expansion. Original long-form audio remains partial.

Full coverage record.

Source date: 2026-11-02. Recorded in this review: November 3, 2026.

Vertex now expects both Phase 3 suzetrigine diabetic-peripheral-neuropathy trials and the Phase 2 VX-993 DPN trial to finish enrollment by end-2026 and report results in mid-2027. Enrollment targets and readout forecasts do not establish enrollment completion, efficacy or safety. No new numerical DPN outcome is disclosed.

Suzetrigine’s U.S. JOURNAVX approval is for moderate-to-severe acute pain in adults; DPN remains investigational. The open-label 52-week extension NCT06696443 is separately active/not recruiting with 455 actual participants and January 25, 2027 estimated completion, but no posted results; it is not the blinded pivotal comparison. VX-993 remains investigational. The forecast does not override trial-specific completion estimates.

Next milestones: Suzetrigine and VX-993 DPN results: 2027-mid (Sponsor forecast; not guaranteed).

Sources: investors.vrtx.com · news release; ClinicalTrials.gov · NCT06696443.

Source date: 2026-11-03. Recorded in this review: November 3, 2026.

The NIH experimental-pain HNK study (NCT07504601) remains not yet recruiting without posted results. Its estimated start is now November 8, replacing November 4. Primary completion December 31, 2030 and final completion December 31, 2031 remain estimates. This administrative change is retained for calendar accuracy and excluded from a new medical-news alert; it does not establish first dosing or patient analgesic benefit.

Next milestones: HNK estimated start: 2026-11-08 (Registry estimate; not yet recruiting).

Sources: ClinicalTrials.gov · NCT07504601.

Coverage and remaining gaps: focused_incomplete. New forecast is not a neuropathy readout or approval. Full Xenon poster denominators, original Mohs-surgery paper and complete chronic-pain/long-form transcript appraisal remain incomplete.

Informal-source coverage: Targeted Reddit/podcast searches returned patient anecdotes or previously recorded development discussions; no distinct original new trial-result rumor selected. Broad complete audio/transcript review remains incomplete.

Full coverage record.

Source date: 2026-10-29. Recorded in this review: October 30, 2026.

Xenon reports healthy-volunteer studies of XEN1701 (NaV1.7 inhibitor; 76 active/22 placebo) and XEN1120 (Kv7 opener; 54/18). Sampling and modeling predict target occupancy or exposures; these are not measured pain relief in patients. The animal analgesia experiments accompanying the release are not human efficacy.

No treatment-related dose-limiting events, serious TEAEs or adverse-event discontinuations were reported; XEN1120 also had no severe TEAEs. Its multiple-dose cohorts had tachycardia 33.2% versus 12.5%, dizziness 29.2% versus 0% and somnolence 25% versus 0%. Exact cohort denominators and full duration/tables were not supplied, so do not apply those percentages to the entire 54/18 sample or infer long-term safety. XEN1701’s autonomic findings lacked a consistent pattern, which is not zero cardiovascular risk.

Both remain investigational, with no U.S. pain approval. Phase 2 acute-pain trials are forecast for H1 2027; designs, first dosing and patient efficacy are not established.

Next milestones: XEN1701/XEN1120 acute-pain Phase 2 starts: 2027-H1 (Sponsor forecast; not confirmed initiation).

Sources: investor.xenon-pharma.com · news release; xenon-pharma.com · PDF document; xenon-pharma.com · PDF document.

Source date: 2026-10-29. Recorded in this review: October 30, 2026.

NCT07905404 plans 79 prospectively treated adults undergoing hip-fracture surgery at Beth Israel Deaconess, compared with approximately 2:1 matched institutional historical controls from 2020–25. The open-label protocol adds labeled suzetrigine dosing to multimodal care for up to 14 days. Primary inpatient opioid exposure through 72 hours/discharge is distinct from pain, rehabilitation, delirium and safety.

The overall record has parallel/nonrandomized fields; it must not be presented as a randomized contemporary-control trial. Matching and propensity methods cannot eliminate changes in care or unmeasured confounding. No results. Adult acute-pain approval already exists; this study is not a new approval or chronic-pain indication. It is not yet recruiting, with January 5, 2027 estimated start and July 30, 2028 primary/final completion.

Next milestones: STRIDE-HIP estimated start: 2027-01-05 (Registry estimate; not yet recruiting).

Sources: ClinicalTrials.gov · NCT07905404.

Source date: 2026-10-30. Recorded in this review: October 30, 2026.

NCT07504601 remains not yet recruiting with no results. Its estimated start is now November 4, 2026, replacing November 1. Primary completion December 31, 2030 and final completion December 31, 2031 remain estimates. This administrative change does not establish first dosing or analgesic efficacy and is excluded from a fresh medical-news alert.

Next milestones: HNK estimated start: 2026-11-04 (Registry estimate; not yet recruiting).

Sources: ClinicalTrials.gov · NCT07504601.

Coverage and remaining gaps: focused_incomplete. Original Xenon poster PDFs were inaccessible, cohort denominators and full safety tables remain incomplete. Patient analgesic efficacy is not established by healthy-volunteer exposure or animal pain experiments. Worldwide and full transcript appraisal incomplete.

Informal-source coverage: No distinct original new development rumor selected; broader Reddit/podcast coverage incomplete. HNK shifted start remains a registry estimate, not confirmed dosing.

Full coverage record.

Source date: 2026-10-27. Recorded in this review: October 27, 2026.

October 27 registry check: NCT07504601, the early (2R,6R)-hydroxynorketamine human pain program, remains not yet recruiting with no results. The estimated start has shifted from October 25 to November 1, 2026. This is an administrative timing update, not confirmed dosing or new efficacy. The program was first registered in April; this check does not turn that earlier baseline into fresh clinical news. No public-results date was verified.

Sources: ClinicalTrials.gov · NCT07504601.

Coverage and remaining gaps: focused_partial. No material new numerical trial result selected from the appraised sources. Some registry records are incidental or not fully appraised; worldwide human trial and informal-source coverage remain incomplete.

Informal-source coverage: No distinct new original rumor selected from targeted web/Reddit leads; full podcast/talk transcripts not covered. HNK start remains an estimate, not a rumor-confirmed milestone.

Full coverage record.

Baseline registration April 1; current record checked October 23 — NCT07504601. NIH plans a 92-person Phase 2 study of (2R,6R)-hydroxynorketamine, a ketamine metabolite, in healthy volunteers. A blinded drug/placebo crossover is accompanied by a separate no-treatment group. The primary outcome concerns experimentally induced pain ratings hours after infusion; brain imaging is also studied.

The study remains not yet recruiting, with an October 25, 2026 estimated start and primary/final estimates December 31, 2030 / December 31, 2031. No efficacy or safety results are available. Laboratory pain sensitivity is not chronic-pain relief, improved daily function, proof of lower abuse liability or an approved indication. This is older program context newly added to the library, not an April result or a fresh treatment approval.

Sources: ClinicalTrials.gov · NCT07504601.

Coverage and remaining gaps: October 20 registry review retrieved all named records and every page of September 5–October 20 discovery (60 records). October 23 extended discovery through October 21–23 (11 records) and rechecked selected priority programs. All retrieval errors were resolved. Retrieval is not exhaustive appraisal: worldwide registries, all primary publications/harms, conference posters and original recordings remain incomplete. Earlier full successful-check dates are preserved.

Informal-source coverage: Targeted original Reddit, interviews, podcasts and saved unresolved-claim searches were checked selectively on October 20 and October 23. Reposts, product promotion and anecdotes do not establish a formal efficacy/safety result; comprehensive original audio/transcript coverage remains incomplete. Original patient comments about Journavx and ketamine-like compounds were not treated as controlled outcomes or new development decisions.

Full coverage record.

Source date: October 8, 2026; enrollment-completion event October 2. Saol reports completed enrollment for BEACON (NCT07226258), randomized masked phase 3 SL1002 versus placebo for knee-OA pain at over twenty U.S. sites. SL1002 is a targeted perineural chemoneurolytic injection. The primary endpoint is week-12 change in walking-pain intensity; this is symptom treatment, not cartilage regeneration.

Limits/safety: No new effect estimate, participant disposition or harms table. The August 25 registry still says recruiting with 150 estimated participants; it is stale relative to the sponsor milestone and does not establish the final analyzed sample. Chronic pain/function, durability and nerve-related harms need comparative results.

U.S./next: Investigational. Sponsor forecasts topline Q2 2027 and plans another phase 3 knee study. A granted End-of-Phase-2 FDA meeting concerns a separate spasticity program; meeting permission is neither agreement on final design nor approval.

October 8 original sponsor release; registry.

Registry updated October 9, 2026. NCT06696443, the suzetrigine painful-diabetic-peripheral-neuropathy extension, is now active, not recruiting, with 455 actual participants. It began December 18, 2024 and has estimated primary/final completion January 25, 2027. The single-arm open-label design primarily assesses adverse and serious adverse events through week 54; symptoms and health status are secondary.

Limits/safety/U.S.: No results are posted. Enrollment closure is not study completion, demonstrated safety or a positive efficacy readout. This extension cannot isolate a treatment effect without a comparator. Suzetrigine’s existing acute-pain approval does not establish a diabetic-neuropathy indication.

Next: Completion is estimated, not a promised result date. Follow the separate randomized pivotal efficacy studies and eventual label decisions.

Primary registry.

First posted October 8, 2026; registry-reported actual start October 7. NCT07864896 plans 148 participants in a randomized, masked phase 3 suzetrigine-versus-placebo trial at Hospital for Special Surgery. Primary total knee arthroplasty patients receive study treatment for fourteen days. The primary endpoint is cumulative opioid consumption over forty-eight hours; secondary pain and opioid-use assessments continue through later postoperative visits.

Limits/safety/U.S.: No results or harms rates. Less rescue opioid use would need interpretation alongside pain control, ambulation and adverse effects. One primary time-frame line mistakenly says THA despite a TKA protocol; retain this registry inconsistency. Research extends evidence for an already acute-pain-approved drug and is not a new chronic-pain approval.

Next: Recruiting; January 2029 primary and January 2030 final completion are month-precision estimates, not publication promises.

Primary registry.

Remaining gaps: All saved named NCT records refreshed and all pages of official overlap discovery screened (49 returned records). Search starts September 5/6 from the last full successful check, not October 6 alone. Incidental matches excluded; literature, international registries, all regulatory files and complete podcast/audio appraisal remain incomplete.; Broad trial discovery also located NIH experimental-pain HNK and another rotator-cuff suzetrigine study, not promoted as patient efficacy. Full VX-993 and other chronic-pain safety, surgery abstracts and international records remain incompletely appraised.

Informal-source coverage: Read original r/anesthesiology Journavx thread. Anonymous clinician/patient accounts conflict on relief and opioid substitution; mixed regimens, uncontrolled samples and unverified insurance claims are not trial outcomes or reliable coverage estimates. No distinctive formal-development rumor selected; full Radiolab/podcast audio not appraised.

Full coverage record.

Baseline source date: Published online August 8, 2026, not a new October trial; October is the journal issue. Evidence: Open-label single-arm phase 4 NCT06887959.

Forty-seven adults undergoing arthroscopic/laparoscopic surgery received suzetrigine within a multimodal analgesic regimen for up to 14 days. Good/very-good/excellent end-of-treatment ratings occurred in 90.9%; 76.1% did not require opioid rescue. One aspiration serious adverse event was considered unrelated.

Limits: Sponsor-supported, small and uncontrolled. Acetaminophen, anti-inflammatory medicines and procedure-specific adjuncts contribute to analgesia; no causal opioid-sparing comparison or chronic-pain efficacy is established.

U.S./next milestone: Existing adult acute-pain approval is separate from investigational chronic uses. Controlled trials remain needed; no readout inferred.

Full primary paper; registry.

Source date: October 2, 2026 first registry posting. Evidence: NCT07856654, planned phase 4 randomized masked study in 48 adults after urogynecologic surgery.

Suzetrigine or matching placebo is added to the same multimodal analgesic background. Primary outcome: seven-day change in pain score. Secondary measures include opioid consumption, recovery satisfaction and tolerability.

Limits/safety/U.S.: Not yet recruiting; no benefit or safety result. Existing acute-pain authorization is not evidence this specific regimen improves recovery.

Next: November 2026 start, December 2027 primary completion and May 2028 final completion are registry estimates, not promised readouts.

Primary registry.

Source/event date: 2026-07-23. Evidence: Peer-reviewed randomized pilot-trial abstract; historical context.

PEPTIDE randomized 44 adults aged 18–60 with chronic inflammatory-like low back pain, Modic type 1 MRI changes and inadequate NSAID response to two daily 90-mg pamidronate infusions or placebo. At three months, the primary pain-score difference was −6.4 mm on a 100-mm scale (95% CI −22.0 to 9.3), without statistically significant benefit. A six-week difference also crossed zero. Adverse events occurred in 54.6% versus 27.3%, mainly influenza-like symptoms. This small trial does not establish durable analgesia, fracture healing or cartilage repair. The paper appeared online July 23 and in a September issue; this is recovered baseline context, not October news. Primary abstract.

Next milestone: No confirmatory-trial milestone or date verified.

Primary abstract.

Source date: 2026-09-25. Event date: 2026-09-25. Evidence: Peer-reviewed cluster randomized trial.

An integrated nonpharmacologic perioperative-care strategy reduced opioid exposure but did not improve its coprimary patient-reported outcomes. NOHARM included 68,141 surgical procedures across 22 practices at six U.S. centers. Adjusted PROMIS differences were .09 for pain interference (95% CI −.18 to .36; p=.51) and .15 for physical function (−.11 to .41; p=.27). Secondary opioid exposure rate ratio was .90 (.82–.99; p=.03). Trial: NCT04570371.

Limitations: Stepped-wedge cluster design; procedure count is not unique-patient count. Prescription/administration records are not complete consumption data. Approximately 70% patient-reported response and a predominantly White single-system population limit generalizability.

Safety: No significant adverse-event or utilization change reported. Reduced opioid exposure is not demonstrated prevention of addiction or mortality.

U.S. status: A care-delivery intervention, not a new drug approval.

Next milestone: Replication and longer-term implementation outcomes; timing unknown.

NOHARM randomized clinical trial, JAMA Network Open.

Source date: 2026-09-21. Event date: 2026-09-21. Evidence: Sponsor topline announcement.

Novo reported improved pain ratings in type 2 diabetes with painful peripheral neuropathy, and plans Phase 3 neuropathy trials across its portfolio during 2027. NCT06797869 randomized quadruple-masked trial: registry enrollment 142; slide analysis n=141. At the registered 32-week endpoint, CagriSema 2.4/2.4 mg reduced PI-NRS by 2.4 points versus 1.3 with placebo, from baseline 6.4; efficacy estimand, on top of standard care. More than 53% of treated participants achieved ≥30% pain reduction; comparator response not supplied.

Limitations: Sponsor slide only, no CI or exact p-value; pain relief is not nerve regeneration or prevention of diabetic complications. Analysis and enrollment denominators differ.

Safety: Only qualitative statement that safety/tolerability resembled prior CagriSema trials; no new quantitative table.

U.S. status: Investigational for this use; no new U.S. approval.

Next milestone: Phase 3 trials in painful diabetic neuropathy during 2027, sponsor plan with no specific start date.

Novo Diabetes CMD, slide 10; NCT06797869 registry.

Related findings:

• CBL-514 reports reduced Dercum lipoma pain in Phase 2.

Source date: 2026-09-17. Evidence: Sponsor protocol-development announcement.

MIRA submitted a phase 2a chemotherapy-induced neuropathy protocol for ethics review; site initiation is targeted for Q1 2027, not confirmed underway. After FDA feedback, the planned randomized double-blind crossover study compares oral Ketamir-2 300 mg, 600 mg and placebo across three seven-day periods with washouts in adults with persistent moderate-to-severe chemotherapy-induced peripheral neuropathy. Enrollment size and a matched registry identifier were not established in the release.

Limitations: Healthy-volunteer phase 1 tolerability does not establish pain relief, function or chronic safety in patients. This oral NMDA-modulator program is distinct from approved suzetrigine and from psychedelic depression trials.

Safety: Sponsor reports no serious events or dose-limiting toxicity in phase 1; phase 2 comparative safety and CNS effects remain unmeasured.

U.S. status: Investigational; FDA protocol review and an active IND are not marketing approval.

Next milestone: Q1 2027 site initiation is conditional on IRB review and activation. An October 5–6 presentation concerns phase 1/development, not phase 2 efficacy.

MIRA, September 17.

Suzetrigine / VX-548 / Journavx is a selective peripheral NaV1.8 sodium-channel inhibitor. The FDA approved it on January 30, 2025 for moderate-to-severe acute pain in adults. Two randomized 48-hour trials after abdominoplasty (NCT05558410) and bunionectomy (NCT05553366) established superiority over placebo on time-weighted pain reduction. A separate open-label trial, NCT05661734, contributed safety data. FDA trial review and approval summary.

The active comparator was hydrocodone/acetaminophen, and rescue ibuprofen was allowed. The studies did not establish superiority to that opioid combination: its average pain-relief score was slightly lower than suzetrigine after abdominoplasty and higher after bunionectomy. Approval therefore should not be restated as proof of superior opioid replacement across surgeries. Common adverse reactions included itching, muscle spasms, creatine-phosphokinase elevation, and rash. Longer treatment and other populations require separate evidence. FDA efficacy and safety tables.

For painful diabetic peripheral neuropathy (DPN), the program includes phase 3 studies NCT06628908 and NCT07231419, plus an open-label long-term study, NCT06696443. Vertex's August 2026 update expects enrollment in both pivotal trials to finish by year-end 2026. That is an enrollment milestone, not a promised results date or a chronic-pain approval. Trial 1; trial 2; long-term study; current sponsor timeline.

Important counterexample: the December 2024 painful lumbosacral radiculopathy phase 2 study reported mean pain reductions of 2.02 points with suzetrigine versus 1.98 with placebo at week 12. Its primary analysis was change within the treated group, which was statistically significant; it was not designed or powered to establish a between-group difference. This does not demonstrate efficacy beyond placebo in radiculopathy, despite the company's “met primary endpoint” description. Sponsor's full phase 2 result.

Vertex's next NaV1.8 inhibitor, VX-993, remains investigational. The company decided not to advance it as acute-pain monotherapy because its phase 2 efficacy did not suggest superiority to suzetrigine. This was a development decision about that use, not discontinuation of the molecule: a phase 2 DPN trial continues, with enrollment completion also projected by the end of 2026. Watch whether any incremental efficacy justifies the new program and whether tolerability remains acceptable over chronic exposure. Vertex annual filing; August 2026 pipeline update.

Tonmya / TNX-102 SL is sublingual cyclobenzaprine, a centrally acting drug with a long-established active ingredient, newly approved for adult fibromyalgia on August 15, 2025. This is a new formulation and indication, not a newly discovered molecular class. Approval announcement; current prescribing information.

The peer-reviewed RESILIENT trial, NCT05273749, analyzed 456 participants over 14 weeks. Average pain decreased by 1.8 points versus 1.2 with placebo, with statistically significant benefits in sleep, fatigue, and other prespecified outcomes. An earlier trial, RALLY, did not significantly separate from placebo; both successes and that failure belong in the record. The studies do not establish superiority to duloxetine, pregabalin, or existing oral cyclobenzaprine. RESILIENT publication; sponsor's three-trial disclosure.

Local mouth reactions are frequent: pooled labeling reports oral numbness in 23% versus 0.7% and somnolence in 6% versus 2%. The label also contains cardiac contraindications and serotonin-syndrome warnings relevant to combinations with some antidepressants. Longer-term effectiveness and comparative tolerability deserve monitoring. Prescribing information.